Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS.

Almeida GS, Bawn CM, Galler M, Wilson I, Thomas HD, Kyle S, Curtin NJ, Newell DR, Maxwell RJ.

NMR Biomed. 2017 Sep;30(9). doi: 10.1002/nbm.3736. Epub 2017 May 22.

PMID:
28543772
2.

Functional characterisation of a novel ovarian cancer cell line, NUOC-1.

McCormick A, Earp E, Elliot K, Cuthbert G, O'Donnell R, Wilson BT, Sutton R, Leeson C, Thomas HD, Blair H, Fordham S, Lunec J, Allan J, Edmondson RJ.

Oncotarget. 2017 Apr 18;8(16):26832-26844. doi: 10.18632/oncotarget.15821.

3.

Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.

Haagensen EJ, Thomas HD, Schmalix WA, Payne AC, Kevorkian L, Allen RA, Bevan P, Maxwell RJ, Newell DR.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1269-1281. Epub 2016 Nov 11.

4.

Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.

Beale G, Haagensen EJ, Thomas HD, Wang LZ, Revill CH, Payne SL, Golding BT, Hardcastle IR, Newell DR, Griffin RJ, Cano C.

Br J Cancer. 2016 Sep 6;115(6):682-90. doi: 10.1038/bjc.2016.238. Epub 2016 Aug 16.

5.

Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.

Haagensen EJ, Thomas HD, Mudd C, Tsonou E, Wiggins CM, Maxwell RJ, Moore JD, Newell DR.

Eur J Cancer. 2016 Mar;56:69-76. doi: 10.1016/j.ejca.2015.12.012. Epub 2016 Jan 25.

PMID:
26820797
6.

The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphoma.

Hunter JE, Butterworth JA, Zhao B, Sellier H, Campbell KJ, Thomas HD, Bacon CM, Cockell SJ, Gewurz BE, Perkins ND.

Oncogene. 2016 Jun 30;35(26):3476-84. doi: 10.1038/onc.2015.399. Epub 2015 Nov 2.

7.

Vasoactivity of rucaparib, a PARP-1 inhibitor, is a complex process that involves myosin light chain kinase, P2 receptors, and PARP itself.

McCrudden CM, O'Rourke MG, Cherry KE, Yuen HF, O'Rourke D, Babur M, Telfer BA, Thomas HD, Keane P, Nambirajan T, Hagan C, O'Sullivan JM, Shaw C, Williams KJ, Curtin NJ, Hirst DG, Robson T.

PLoS One. 2015 Feb 17;10(2):e0118187. doi: 10.1371/journal.pone.0118187. eCollection 2015.

8.

DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, Televantou D, Thomas HD, Jackson J, Burt AD, Newell D, Rose J, Manas DM, Shapiro GI, Curtin NJ, Reeves HL.

Clin Cancer Res. 2015 Feb 15;21(4):925-33. doi: 10.1158/1078-0432.CCR-14-0842. Epub 2014 Dec 5.

9.

The conditioned place preference test for assessing welfare consequences and potential refinements in a mouse bladder cancer model.

Roughan JV, Coulter CA, Flecknell PA, Thomas HD, Sufka KJ.

PLoS One. 2014 Aug 6;9(8):e103362. doi: 10.1371/journal.pone.0103362. eCollection 2014.

10.

The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.

Haagensen EJ, Thomas HD, Wilson I, Harnor SJ, Payne SL, Rennison T, Smith KM, Maxwell RJ, Newell DR.

PLoS One. 2013 Dec 10;8(12):e81763. doi: 10.1371/journal.pone.0081763. eCollection 2013.

11.

Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling.

Hepburn AC, Veeratterapillay R, Williamson SC, El-Sherif A, Sahay N, Thomas HD, Mantilla A, Pickard RS, Robson CN, Heer R.

PLoS One. 2012;7(11):e50690. doi: 10.1371/journal.pone.0050690. Epub 2012 Nov 30.

12.

Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.

Hill CR, Jamieson D, Thomas HD, Brown CD, Boddy AV, Veal GJ.

Biochem Pharmacol. 2013 Jan 1;85(1):29-37. doi: 10.1016/j.bcp.2012.10.004. Epub 2012 Oct 11.

13.

Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues.

Jarvis IW, Meczes EL, Thomas HD, Edmondson RJ, Veal GJ, Boddy AV, Ottley CJ, Pearson DG, Tilby MJ.

Biochem Pharmacol. 2012 Jan 1;83(1):69-77. doi: 10.1016/j.bcp.2011.10.005. Epub 2011 Oct 14.

PMID:
22015635
14.

The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.

Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Babur M, Telfer BA, Curtin NJ, Williams KJ.

Mol Cancer Ther. 2011 Dec;10(12):2320-9. doi: 10.1158/1535-7163.MCT-11-0356. Epub 2011 Sep 16.

15.

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK, Shapiro GI.

Nat Med. 2011 Jun 26;17(7):875-82. doi: 10.1038/nm.2377.

16.

Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301.

Thomas HD, Wang LZ, Roche C, Bentley J, Cheng Y, Hardcastle IR, Golding BT, Griffin RJ, Curtin NJ, Newell DR.

Eur J Cancer. 2011 Sep;47(13):2052-9. doi: 10.1016/j.ejca.2011.04.008. Epub 2011 May 12.

PMID:
21570822
17.

Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers.

Zaremba T, Thomas HD, Cole M, Coulthard SA, Plummer ER, Curtin NJ.

Biochem J. 2011 Jun 15;436(3):671-9. doi: 10.1042/BJ20101723.

PMID:
21434873
18.

Nucleoside transport inhibitors: structure-activity relationships for pyrimido[5,4-d]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of α1-acid glycoprotein.

Saravanan K, Barlow HC, Barton M, Calvert AH, Golding BT, Newell DR, Northen JS, Curtin NJ, Thomas HD, Griffin RJ.

J Med Chem. 2011 Mar 24;54(6):1847-59. doi: 10.1021/jm101493z. Epub 2011 Mar 2.

PMID:
21366300
19.

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ.

J Natl Cancer Inst. 2011 Feb 16;103(4):334-46. doi: 10.1093/jnci/djq509. Epub 2010 Dec 23.

PMID:
21183737
20.

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, Clifford SC, Curtin NJ.

Br J Cancer. 2010 Nov 9;103(10):1588-96. doi: 10.1038/sj.bjc.6605946. Epub 2010 Oct 26.

21.

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

Issaeva N, Thomas HD, Djureinovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C, Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ, Helleday T.

Cancer Res. 2010 Aug 1;70(15):6268-76. doi: 10.1158/0008-5472.CAN-09-3416. Epub 2010 Jul 14. Erratum in: Cancer Res. 2010 Oct 1;70(19):7734. Djurenovic, Tatjana [corrected to Djureinovic, Tatjana].

22.

Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?

Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD, Kamjoo M, Kyle S, Robson T, Shaw C, Hirst DG, Curtin NJ, Williams KJ.

Clin Cancer Res. 2009 Oct 1;15(19):6106-12. doi: 10.1158/1078-0432.CCR-09-0398. Epub 2009 Sep 29.

23.

Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity.

Thomas HD, Saravanan K, Wang LZ, Lin MJ, Northen JS, Barlow H, Barton M, Newell DR, Griffin RJ, Golding BT, Curtin NJ.

Mol Cancer Ther. 2009 Jul;8(7):1828-37. doi: 10.1158/1535-7163.MCT-08-1208. Epub 2009 Jun 9.

24.

Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.

Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, Hostomsky Z, Plummer ER, Boddy AV, Tweddle DA, Curtin NJ, Clifford SC.

Clin Cancer Res. 2009 Feb 15;15(4):1241-9. doi: 10.1158/1078-0432.CCR-08-1095. Epub 2009 Jan 27.

25.

Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.

Kyle S, Thomas HD, Mitchell J, Curtin NJ.

Br J Radiol. 2008 Oct;81 Spec No 1:S6-11. doi: 10.1259/bjr/99111297.

PMID:
18820000
26.

Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo.

Armstrong JL, Taylor GA, Thomas HD, Boddy AV, Redfern CP, Veal GJ.

Br J Cancer. 2007 Jun 4;96(11):1675-83. Epub 2007 May 8.

27.

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.

Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, Maegley KA, Newell DR, Skalitzky D, Wang LZ, Webber SE, Curtin NJ.

Mol Cancer Ther. 2007 Mar;6(3):945-56.

28.

An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed.

Graham-Cole CL, Thomas HD, Taylor GA, Newell DR, Melton RG, Hesp R, Boddy AV.

Cancer Chemother Pharmacol. 2007 Feb;59(2):197-206. Epub 2006 May 24.

PMID:
16721548
29.

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, Calvert AH, Newell DR, Smith GC, Curtin NJ.

Cancer Res. 2006 May 15;66(10):5354-62.

30.

Biliary excretion of etoposide in children with cancer.

Veal GJ, Errington J, Thomas HD, Boddy AV, Lowis S.

Cancer Chemother Pharmacol. 2006 Sep;58(3):415-7. Epub 2006 Jan 18.

PMID:
16418874
31.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T.

Nature. 2005 Apr 14;434(7035):913-7. Erratum in: Nature. 2007 May 17;447(7142):346.

32.

Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.

Tikhe JG, Webber SE, Hostomsky Z, Maegley KA, Ekkers A, Li J, Yu XH, Almassy RJ, Kumpf RA, Boritzki TJ, Zhang C, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR.

J Med Chem. 2004 Oct 21;47(22):5467-81.

PMID:
15481984
33.

Results from a practice-based lipid clinic model in achieving low density lipoprotein cholesterol goals.

Thomas HD, Maynard C, Wagner GS, Eisenstein EL.

N C Med J. 2003 Nov-Dec;64(6):263-6.

PMID:
14983613
34.

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ.

J Natl Cancer Inst. 2004 Jan 7;96(1):56-67.

PMID:
14709739
35.

Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.

Calabrese CR, Batey MA, Thomas HD, Durkacz BW, Wang LZ, Kyle S, Skalitzky D, Li J, Zhang C, Boritzki T, Maegley K, Calvert AH, Hostomsky Z, Newell DR, Curtin NJ.

Clin Cancer Res. 2003 Jul;9(7):2711-8.

36.

Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.

Canan Koch SS, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li J, Yu XH, Zook SE, Kumpf RA, Zhang C, Boritzki TJ, Mansour RN, Zhang KE, Ekker A, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR, Webber SE, Hostomsky Z.

J Med Chem. 2002 Nov 7;45(23):4961-74.

PMID:
12408707
37.

Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.

Thomas HD, Porter DJ, Bartelink I, Nobbs JR, Cole M, Elliott S, Newell DR, Calvert AH, Highley M, Boddy AV.

Br J Clin Pharmacol. 2002 Jan;53(1):83-91.

38.

Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer.

Boddy AV, Griffin MJ, Sludden J, Thomas HD, Fishwick K, Wright JG, Plumner ER, Highley M, Calvert AH.

Cancer Chemother Pharmacol. 2001 Jul;48(1):15-21.

PMID:
11488519
39.

In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity.

Smith PG, Thomas HD, Barlow HC, Griffin RJ, Golding BT, Calvert AH, Newell DR, Curtin NJ.

Clin Cancer Res. 2001 Jul;7(7):2105-13.

40.

Hypoxanthine transport in human tumour cell lines: relationship to the inhibition of hypoxanthine rescue by dipyridamole.

Marshman E, Taylor GA, Thomas HD, Newell DR, Curtin NJ.

Biochem Pharmacol. 2001 Feb 15;61(4):477-84.

PMID:
11226382
41.

Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours.

Thomas HD, Lind MJ, Ford J, Bleehen N, Calvert AH, Boddy AV.

Cancer Chemother Pharmacol. 2000;45(4):284-90.

PMID:
10755316
42.

High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours.

Bisogno G, Cowie F, Boddy A, Thomas HD, Dick G, Pinkerton CR.

Br J Cancer. 1998 Jun;77(12):2304-9.

43.

RMP-7 : Potential as an Adjuvant to the Drug Treatment of Brain Tumours.

Boddy AV, Thomas HD.

CNS Drugs. 1997 Apr;7(4):257-63. doi: 10.2165/00023210-199707040-00001.

PMID:
27520751
44.

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.

Siddiqui N, Boddy AV, Thomas HD, Bailey NP, Robson L, Lind MJ, Calvert AH.

Br J Cancer. 1997;75(2):287-94.

45.

A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.

Laohavinij S, Wedge SR, Lind MJ, Bailey N, Humphreys A, Proctor M, Chapman F, Simmons D, Oakley A, Robson L, Gumbrell L, Taylor GA, Thomas HD, Boddy AV, Newell DR, Calvert AH.

Invest New Drugs. 1996;14(3):325-35.

PMID:
8958188
46.

Polymorphism of a CAG trinucleotide repeat within Sry correlates with B6.YDom sex reversal.

Coward P, Nagai K, Chen D, Thomas HD, Nagamine CM, Lau YF.

Nat Genet. 1994 Mar;6(3):245-50.

PMID:
8012385
47.
48.

Fifty years of cardiology in Alabama.

Thomas HD.

J Med Assoc State Ala. 1981 Jul;51(1):19-20. No abstract available.

PMID:
7040573
49.

Respiratory oxygen debt and excess lactate in man.

Thomas HD, Gaos C, Vaughan CW.

J Appl Physiol. 1965 Sep;20(5):898-904. No abstract available.

PMID:
4284418
50.

CIRCULATORY AND VENTILATORY RESPONSES TO POSTPRANDIAL EXERCISE.

JONES WB, THOMAS HD, REEVES TJ.

Am Heart J. 1965 May;69:668-76. No abstract available.

PMID:
14280108

Supplemental Content

Loading ...
Support Center